title: Behçet disease-associated uveitis successfully treated with golimumab.
abstract: Over the past decade, the off-label use of biologic agents such as TNF-α antagonists, including infliximab and adalimumab, has improved the treatment armamentarium for refractory immune-mediated uveitis, with particular success in Behçet disease-associated uveitis. Golimumab is a novel fully human anti-TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with very promising results. Herein, the authors present the use of GLM in a case of Behçet uveitis refractory to other TNF-α blockers. There are only two reports in the literature about the use of GLM in uveitis, describing four patients with JIA-associated uveitis and a case of idiopathic retinal vasculitis. To the authors' knowledge, this is the first report about the use of GLM in Behçet uveitis.
authors.affiliation: Ophthalmology Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
authors.forename: Marina
authors.initials: M
authors.lastname: Mesquida
authors.forename: María
authors.initials: M
authors.lastname: Victoria Hernández
authors.forename: Victor
authors.initials: V
authors.lastname: Llorenç
authors.forename: Laura
authors.initials: L
authors.lastname: Pelegrín
authors.forename: Gerard
authors.initials: G
authors.lastname: Espinosa
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Dick
authors.forename: Alfredo
authors.initials: A
authors.lastname: Adán
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab